NOT-NS-21-006 - Notice of Intent to Publish a Funding Opportunity Announcement for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
NOT-NS-21-007 - Notice of Intent to Publish a Funding Opportunity Announcement for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
Reissuance of PAR-18-763: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
National Institute of Neurological Disorders and Stroke (NINDS)
The purpose of this Notice is to inform potential applicants that the National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a re-issuance of funding opportunity announcement (FOA) PAR-18-763.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The FOA is expected to be published in February 2021 with an expected application due date in summer 2021.
This FOA will utilize the R61/R33 activity code. Details of the planned FOA are provided below.
This funding opportunity announcement (FOA) encourages the development and validation of animal models and human/animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models or ex vivo systems that will be utilized to facilitate the development of neurotherapeutics. Ideally, models proposed for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program focused on enabling the exploratory and early stages of drug discovery.
Applicants are strongly encouraged to consult with NINDS program staff as plans for an application are being developed.
TBD.
TBD.
Direct costs cannot exceed $499,000 in any one year. Cumulative direct costs for the entire 3-year project period may not exceed $750,000.
93.853
Applications are not being solicited at this time.
Please direct all inquiries to:
Rebecca Roof, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
301-496-1779
[email protected]
Julia Bachman, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
301-496-1779
[email protected]